# Flare Therapeutics

**Canonical:** https://apis.io/providers/flare-therapeutics/  
**Website:** https://www.flaretx.com/  
**APIs profiled:** 1

Flare Therapeutics is a clinical-stage biotechnology company headquartered at 400 Technology Square, Cambridge, Massachusetts, developing small-molecule precision medicines against transcription factors — a target class long considered undruggable. Its platform combines a "switch site" hypothesis with cell-based ligand discovery and chemoproteomics to find binding pockets on transcription factors that control cancer cell states. The company launched publicly in May 2021 with an $82 million Series A led by Third Rock Ventures, and closed an $85 million insider-led Series C on 30 June 2026 led by Third Rock Ventures and Nextech Invest with Pfizer Ventures, Boxer Capital, GordonMD Global Investments, Invus, Casdin Capital, Eli Lilly, Novartis, Agent Capital and Eventide Asset Management participating, appointing Anna Protopapas as Chief Executive Officer at the same time. Its clinical-stage lead FX-909 is a PPARG inverse agonist in advanced urothelial cancer; FX-111 is an androgen-receptor-directed program in prostate cancer that received FDA IND clearance ahead of a clinical start in the third quarter of 2026. Flare also runs a discovery collaboration with Roche on undrugged transcription factor targets in oncology. Flare Therapeutics operates no developer program and publishes no product API, developer portal or API documentation. The only machine-readable surface reachable without credentials is the WordPress REST content API behind www.flaretx.com, catalogued here.

## Kin Score — 30.9 / 100 (thin)

Scored 2026-08-17 under rubric 0.11.0. Trend: flat (+0.0 from 30.9).

| Facet | Score |
|---|---|
| Discoverability | 75.9 |
| Contract Quality | 49.3 |
| Governance | 20.8 |
| Operational Transparency | 5.3 |
| Developer Ergonomics | 17.4 |
| Commercial Clarity | 21.1 |

Regulatory layer — **Health**: 31.3 (matched via tags).

## Agent readiness — 36.5 (agent-ready)

| Dimension | Value |
|---|---|
| Spec Presence | yes |
| Agentic Access | no |
| MCP Server | no |
| Auth Clarity | yes |
| Idempotency | no |
| Error Semantics | documented |
| OpenAPI Examples | no |
| Rate Limit Signal | documented |
| Event Surface Described | no |
| Agent Skills | yes |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## APIs (1)

- **Flare Therapeutics Content API** — The anonymously readable WordPress REST content API behind www.flaretx.com — the 42-item corporate news archive, 14 corporate pages, a 419-item media library, the category taxon...

## Security (2)

- **Flare Therapeutics Authentication** — 0 schemes
- **Flare Therapeutics Domain Security** — TLSv1.3 · HSTS · DMARC

## Plans (1)

- **Flare Therapeutics Plans Pricing**

## Tags

Company, biotechnology, pharmaceuticals, oncology, precision-medicine, transcription-factors, drug-discovery, clinical-trials, life-sciences, content-api

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/flare-therapeutics/). Scores are computed from the provider's own public artifacts under a published rubric.